Focus: Shattuck Labs is a public-stage immunotherapy platform company focused on oncology, headquartered in Austin, TX. The company is in early-stage clinical development with a portfolio of Phase 1 programs.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
Shattuck Labs is a high-risk, early-stage immunotherapy bet suitable only for candidates comfortable with preclinical/early-clinical science, tight resource environments, and material dilution risk.
Help build intelligence for Shattuck Labs
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Shattuck Labs's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
8-K Filing: Shattuck Labs, Inc. (STTK) (CIK 0001680367) — EX-99.1
EX-99.1
Shattuck Labs Stock Surges Following Positive Analyst Coverage - HarianBasis.co
Shattuck Labs Stock Surges Following Positive Analyst Coverage HarianBasis.co
Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL) and Shattuck Labs (STTK) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL) and Shattuck Labs (STTK) The Globe and Mail
Why Shattuck Labs Stock Soared More Than 53% Higher This Week - The Motley Fool
Why Shattuck Labs Stock Soared More Than 53% Higher This Week The Motley Fool
Shattuck Labs stock maintained at Buy by TD Cowen on drug data - Investing.com
Shattuck Labs stock maintained at Buy by TD Cowen on drug data Investing.com
Clinical Data Optimism Combined with Analyst Recommendation Drives Shattuck Labs Shares Up 53% This Week - NAI500
Clinical Data Optimism Combined with Analyst Recommendation Drives Shattuck Labs Shares Up 53% This Week NAI500
Showing 6 of 7 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.
First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo